Latest Articles about GHDX

Biotech Companies See Insider Purchases: CEO Phillip Frost Increases Stake in OPKO and Felix Baker Buys ACADIA

Josh Wolonick — Mon, 20 May 2013 19:20:00 Z

Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside sales and purchases filed with the SEC on Friday, May 17, 2013. Purchases: Felix Baker, a

In Insider Trading, Harbinger Buys Spectrum Brands Stock for 11th Time Since April 9

Jonathan Moreland — Fri, 17 May 2013 19:17:00 Z

Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside sales and purchases filed with the SEC on Thursday, May 16, 2013. Purchases: The investment

Much Awaited Test Launch by Genomic - Analyst Blog

Zacks Equity Research — Wed, 15 May 2013 23:28:47 Z

Recently, Genomic Health Inc. ( GHDX ) made available its lead pipeline candidate Oncotype DX prostate cancer test to physicians and their patients. This comes as a major boost to the

An Insider Sells Major Stake of General Growth Properties While Directors at Genomic Health and US Steel Buy Stock

Josh Wolonick — Wed, 15 May 2013 18:23:00 Z

Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside sales and purchases filed with the SEC on Tuesday, May 14, 2013. Purchases: Felix Baker, a

Genomic Gains Coverage for DCIS - Analyst Blog

Zacks Equity Research — Mon, 13 May 2013 23:17:06 Z

Genomic Health Inc. ( GHDX ) continues to make strides towards establishing coverage for its Oncotype DX breast cancer test. The company disclosed that the assigned contractor for its

GHDX Reports Loss, Beats on Revs - Analyst Blog

Zacks Equity Research — Mon, 13 May 2013 18:18:48 Z

Genomic Health ( GHDX ) reported first-quarter 2013 net loss of $0.9 million, down from a net income of $0.8 million in the year-ago period. The company's reported loss of 3 cents per share

GHDX to Show Prostate Test Result - Analyst Blog

Zacks Equity Research — Sat, 06 Apr 2013 00:06:16 Z

Keeping in line with its strategy to launch its prostate cancer test by the first half of 2013, Genomic Health, Inc. ( GHDX ) set a presentation at the American Urological Association

Plethora of Positive Data for GHDX - Analyst Blog

Zacks Equity Research — Tue, 19 Mar 2013 01:45:24 Z

Genomic Health Inc. ( GHDX ) continues to demonstrate the clinical and economic merits of its Oncotype DX breast cancer test. The company recently featured positive data from 22 clinical

Genomic Health Reveals Positive Results - Analyst Blog

Zacks Equity Research — Fri, 15 Mar 2013 01:47:59 Z

Recently, Genomic Health ( GHDX ) announced the positive result of a study on Oncotype DX to estimate the risk of loco-regional recurrence (LRR) in node-positive, estrogen receptor breast

Genomic Reports 2 Study Results - Analyst Blog

Zacks Equity Research — Wed, 06 Mar 2013 03:40:01 Z

Recently, Genomic Health ( GHDX ) announced the results of 2 studies, which were conducted to determine RNA-Sequencing and Mutation Identification, in the 14th Annual Advances in Genome

Genomic Beats Estimates - Analyst Blog

Zacks Equity Research — Fri, 08 Feb 2013 18:40:01 Z

Genomic Health ( GHDX ) reported fourth-quarter 2012 net income of $2.0 million, down from $2.6 million in the year-ago period. The company's reported earnings per share (EPS) of 6 cents

Neutral on Genomic Health - Analyst Blog

Zacks Equity Research — Wed, 09 Jan 2013 00:50:01 Z

We reaffirm our long-term 'Neutral' recommendation on Genomic Health ( GHDX ) following the third quarter results. Despite an impressive growth trajectory, the financial results of this

Genomic Presents Oncotype Results - Analyst Blog

Zacks Equity Research — Thu, 13 Dec 2012 20:50:01 Z

Genomic Health ( GHDX ), an oncology based biotech company, presented the results from 6 studies of the Oncotype DX breast cancer test at the San Antonio Breast Cancer Symposium earlier

Mid-Day Market Update: Monster Worldwide Continues to Rise While Markets Fall

Benzinga — Thu, 08 Nov 2012 23:14:31 Z

Midway through trading Thursday, the Dow traded down 0.42 percent to 12,877.82 while the NASDAQ fell 0.74 percent to 2,915.64. The S&P also fell, decreasing 0.57 percent to 1,386.52.

Mixed 3Q for Genomic Health - Analyst Blog

Zacks Equity Research — Thu, 08 Nov 2012 19:50:01 Z

Genomic Health ( GHDX ) reported third quarter 2012 net income of $3.7 million, up from $3.2 million in the year-ago period. The company's reported earnings per share (EPS) of 11 cents